Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Inhibrx, Inc. (INBX : NSDQ)
 
 • Company Description   
Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.

Number of Employees: 112

 
 • Price / Volume Information   
Yesterday's Closing Price: $13.73 Daily Weekly Monthly
20 Day Moving Average: 454,769 shares
Shares Outstanding: 39.04 (millions)
Market Capitalization: $535.98 (millions)
Beta: 3.06
52 Week High: $47.90
52 Week Low: $12.46
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -22.56% -15.15%
12 Week -36.32% -30.90%
Year To Date -68.56% -62.61%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
11025 NORTH TORREY PINES ROAD SUITE 200
-
LA JOLLA,CA 92037
USA
ph: 858-795-4220
fax: -
amy@juniper-point.com http://www.inhibrx.com
 
 • General Corporate Information   
Officers
Mark P. Lappe - Chief Executive Officer and Chairman
Kelly D. Deck - Chief Financial Officer
Jon Faiz Kayyem - Director
Douglas G. Forsyth - Director
Kimberly Manhard - Director

Peer Information
Inhibrx, Inc. (CORR.)
Inhibrx, Inc. (RSPI)
Inhibrx, Inc. (CGXP)
Inhibrx, Inc. (BGEN)
Inhibrx, Inc. (GTBP)
Inhibrx, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45720L107
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 39.04
Most Recent Split Date: (:1)
Beta: 3.06
Market Capitalization: $535.98 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.84 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.96 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 19.60
Price/Cash Flow: -
Price / Sales: 73.71
EPS Growth
vs. Year Ago Period: -56.86%
vs. Previous Quarter: -45.45%
Sales Growth
vs. Year Ago Period: 4.50%
vs. Previous Quarter: -67.47%
ROE
03/31/22 - -246.26
12/31/21 - -176.32
09/30/21 - -150.02
ROA
03/31/22 - -64.34
12/31/21 - -59.90
09/30/21 - -58.02
Current Ratio
03/31/22 - 7.48
12/31/21 - 6.20
09/30/21 - 4.73
Quick Ratio
03/31/22 - 7.48
12/31/21 - 6.20
09/30/21 - 4.73
Operating Margin
03/31/22 - -1,289.14
12/31/21 - -1,130.80
09/30/21 - -1,093.94
Net Margin
03/31/22 - -1,289.14
12/31/21 - -1,130.80
09/30/21 - -1,093.94
Pre-Tax Margin
03/31/22 - -1,289.14
12/31/21 - -1,130.77
09/30/21 - -1,093.88
Book Value
03/31/22 - 0.70
12/31/21 - 1.38
09/30/21 - 0.74
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 4.16
12/31/21 - 1.44
09/30/21 - 2.68
Debt-to-Capital
03/31/22 - 80.61
12/31/21 - 59.04
09/30/21 - 72.82
 

Powered by Zacks Investment Research ©